<!doctype html>
<html>
<head>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width">
<title></title>
<link rel="stylesheet" href="css/style.css">
</head>

<body>

<header>
  <div class="l"><a href="javascript:history.back();"><span>left</span></a></div>
  <p class="title"><a href="index.html">社外秘 研修資料</a></p>
  <div class="r"><a href="229.html"><span>right</span></a></div>
</header>

<div class="wrap">
  <div class="clearfix">
  <img src="img04/ver4.png" alt="ver4" width="50" height="20" style="float: right;">
  <img src="img04/multi.png" alt="マルチスタジオ非掲載" width="110" height="20" style="float: right;">
  </div>
  <!--タイトルエリア-->
  <section>
    <h1 class="tit">有害事象はMTX中止群よりもMTX継続群の方が多い傾向（COMP-ACT Study）</h1>
  </section>
  <!--タイトルエリア-->

  <!--ボックス-->
  <section>
    <ul class="circle">
  <li><span>●</span>TCZ-SCとMTX併用で低疾患活動性を達成した患者において、併用療法継続群に対する、MTX中止群の非劣性を検証</li>
  <li><span>●</span>主要：TCZ単剤とTCZ＋MTX群の24週から40週のΔDASの比較(非劣性マージン0.6) </li>
  <li><span>●</span>副次：40週と52週のDAS28-Rem, LDA及びACR20/50/70の達成率と安全性 </li>
</ul>
    <div class="img"><img src="img04/228-.png" alt=""></div>
		<div class="table">
      <div class="sc">
        <table class="style1">
          <tr>
            <th>　</th>
            <th>TCZ単剤<br>
(n = 144) 92.44 PY</th>
            <th>TCZ + MTX<br>
 (n = 130) 90.56 PY</th>
          </tr>
          <tr class="graybg">
          	<td colspan="3" class="left"><strong>有害事象</strong></td>
          </tr>
          <tr>
          	<td class="left">　<strong>No. of adverse    events, n</strong></td>
          	<td>220</td>
          	<td>279</td>
          </tr>
          <tr class="graybg">
          	<td class="left">　<strong>Patients with &#8805; 1, n (%)</strong></td>
          	<td>89 (61.8)</td>
          	<td>94 (67.6)</td>
          </tr>
          <tr>
          	<td class="left">　<strong>Events per 100 PY, n (95% CI)</strong></td>
          	<td>238.00<br>
(207.58 to 271.61)</td>
          	<td>308.07<br>
(272.98 to 346.43)</td>
          </tr>
          <tr class="graybg">
          	<td colspan="3" class="left"><strong>重篤有害事象</strong></td>
         	</tr>
          <tr>
          	<td class="left">　<strong>No. of serious adverse events, n</strong></td>
          	<td>8</td>
          	<td>13</td>
          </tr>
          <tr class="graybg">
          	<td class="left">　<strong>Patients with &#8805; 1, n (%)</strong></td>
          	<td>6 (4.2)</td>
          	<td>8 (5.8)</td>
          </tr>
          <tr>
          	<td class="left">　<strong>Events per 100 PY, n (95% CI)</strong></td>
          	<td>8.65 (3.74 to 17.05)</td>
          	<td>14.35 (7.64 to 24.55)</td>
          </tr>
          <tr class="graybg">
          	<td colspan="3" class="left"><strong>重篤感染症</strong></td>
         	</tr>
          <tr>
          	<td class="left">　<strong>No. of serious infections, n</strong></td>
          	<td>3</td>
          	<td>4</td>
          </tr>
          <tr class="graybg">
          	<td class="left">　<strong>Patients with &#8805; 1, n (%)</strong></td>
          	<td>3 (2.1)</td>
          	<td>3 (2.2)</td>
         	</tr>
          <tr>
          	<td class="left">　<strong>Events per 100 PY, n (95% CI)</strong></td>
          	<td>3.25<br>
          		(0.67 to 9.48)</td>
          	<td>4.42<br>
          		(1.20 to 11.31)</td>
          </tr>
        </table>
      </div>
    </div>
    <p class="txt center"><font color="red">TCZ + MTXは、TCZ-MONOよりAE、SAE及び重篤感染の頻度が高い</font></p>

<div class="greenbox"><p><br>ACT-SC+MTXで低疾患活動性を達成した患者ではMTXを中止しても、疾患活動性を維持できる上に、継続群よりも有害事象が少ない傾向にある<br>&nbsp;</p></div>
<p class="text sml right"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29575803">J. Kremer, et al. Arthritis Rheumatol. 2018 Mar 25. doi: 10.1002/art.40493. [Epub ahead of print]</a>
</p>
<p class="text sml right">Joel Kremer, et al. ACR2017. #1905</p>
  </section>
  <!--ボックス-->
</div>

<footer>
  <div class="l"><a href="javascript:history.back();"><span>left</span></a></div>
  <div class="home"><a href="index.html"><span>HOME</span></a></div>
  <div class="r"><a href="229.html"><span>right</span></a></div>
  <div class="pagetop"><a href="javascript:scroll(0,0);">pagetop</a></div>
</footer>

<script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.2/jquery.min.js"></script>
<script src="js/common.js"></script>
</body>
</html>
